Benign prostate hyperplasia (BPH) is a highly prevalent disease. Contemporarily, medical management constitutes the mainstay approach in treating BPH patients. Alpha-blockers and 5-alpha reductase inhibitors are widely utilized alternatives. Combination of these two different groups of agents provides better results. However, the underlying pathophysiology of the BPH related lower urinary symptoms has not been clearly defined. A new promising strategy is to use of phosphodiesterase type 5 (PDE-5) inhibitors in the management of BPH. Therefore, the next step may be the usage of a triple combination for medical management of BPH. However, the major drawback of the combination therapies is the significant cost.